Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Scientists develop new method to identify factors that suppress cancer gene expression

Scientists develop new method to identify factors that suppress cancer gene expression

Zebrafish research suggests new drug targets and markers to help treat melanoma

Zebrafish research suggests new drug targets and markers to help treat melanoma

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

Court grants motion to dismiss Cryo-Cell International lawsuit against Cord Blood America

Court grants motion to dismiss Cryo-Cell International lawsuit against Cord Blood America

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Artemisinin or high-pressure oxygen can boost natural cancer remedy

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Aflac announces $1.06 million scholarship awards for cancer research

Aflac announces $1.06 million scholarship awards for cancer research

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Leukemia & Lymphoma publishes CTI's CPOP phase I/II trial results against NHL

Scientists identify new treatment target for squamous cell lung cancer

Scientists identify new treatment target for squamous cell lung cancer

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies launches new TaqMan Mutation Detection Assays

Report shows a continued decline in diagnoses, deaths for many types of cancers

Report shows a continued decline in diagnoses, deaths for many types of cancers

Rsearchers define new step that controls programmed cell death in cancer cells

Rsearchers define new step that controls programmed cell death in cancer cells

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

New lifesaving technology can combat cancer

New lifesaving technology can combat cancer

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Asuragen launches new miRNA Biofluids service offering

Asuragen launches new miRNA Biofluids service offering

Two new studies on cancer

Two new studies on cancer

Positive outcomes from imatinib trial in both older and younger patients with CML

Positive outcomes from imatinib trial in both older and younger patients with CML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.